ANN PARKER: Open Payments
NPI 1588965784 · BOWIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$386 in 15 payments from 9 companies in 2025. Trend: 2023 $678 · 2024 $395 · 2025 $386
Food & beverage: $386
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $95 |
| Mallinckrodt Hospital Products Inc. | 2 | $62 |
| Merck Sharp & Dohme LLC | 2 | $54 |
| Veloxis Pharmaceuticals, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 1 | $30 |
| ABBVIE INC. | 1 | $30 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $19 |
Products named: XIFAXAN, TERLIVAZ, PREVYMIS, ENVARSUS, Cresemba, MAVYRET, OCALIVA, Wegovy.
Industry payments across MD — which companies pay providers there.
